tirzepatide surpass 2 Once Weekly in Children and Adolescents with Type Diabetes ( SURPASS-Peds). The New England Journal of Medicine. 2024;391:XXX–XXX. doi:10.1056/NEJMoa2400938 New research from the SURPASS-EARLY

B12 is one important piece, but persistent exhaustion usually has more than one contributing factor

Common side effects to monitor Tirzepatide can cause gastrointestinal side effects, especially during the early weeks or after dose increases

Someone with high baseline cortisol or sodium consumption may experience more pronounced fluid loss early in treatment, while those with efficient sodium regulation may notice subtler changes

Potential therapeutic role of L-Carnitine in skeletal muscle oxidative stress and atrophy conditions

Chronic high-fat feeding and prolonged fasting in liver-specific ANGPTL4 knockout mice

Administered as a once-weekly subcutaneous injection, tirzepatide has demonstrated significant efficacy in lowering hemoglobin A1c levels and promoting substantial weight loss in clinical trials